Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)
Status:
Active, not recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
The phase II APPLE trial gives the opportunity to prospectively validate liquid biopsies as a
new standard for testing tumor progression compared with conventional radiological procedure
in EGFR mutant advanced NSCLC patients. Moreover based on the sequential T790M test during
treatment the investigators will assess the predictive value of liquid biopsies. APPLE trial
will examine the best strategy for delivering osimertinib (upfront versus sequential
treatment after 1st generation EGFR TKI) in EGFR mutant NSCLC patients. Finally, the trial
will also explore the mechanisms of acquired resistance to Osimertinib based on the results
of an optional biopsy upon progression.
Phase:
Phase 2
Details
Lead Sponsor:
European Organisation for Research and Treatment of Cancer - EORTC